Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GLYCEROL PHENYLBUTYRATE vs ISOLYTE E IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Glycerol phenylbutyrate is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This compound is excreted by the kidneys, providing an alternative pathway for waste nitrogen excretion in patients with urea cycle disorders.
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
Adjunctive therapy for chronic management of patients with urea cycle disorders involving deficiencies of carbamoyl phosphate synthetase I, ornithine transcarbamylase, or argininosuccinic acid synthetase. It is indicated for all patients requiring therapy for these disorders except those with arginase deficiency.
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
450-600 mg/m2/day orally in three divided doses, rounded to the nearest 100 mg; maximum 20 g/day.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
0.8–1 hours (glycerol phenylbutyrate); 1.2–1.5 hours (phenylacetate); clinical context: short half-life requires thrice-daily dosing
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Glycerol phenylbutyrate is metabolized by lipases to phenylbutyrate, which is then beta-oxidized to phenylacetate. Phenylacetate conjugates with glutamine via acyl-Co A synthetase and acyl-Co A:glutamine N-acyltransferase to form phenylacetylglutamine.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Renal: >90% as phenylbutyrate metabolites (mainly phenylacetylglutamine) within 24 hours; fecal: <1%
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
80–90% bound to albumin (phenylacetate and phenylbutyrate)
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
0.2–0.3 L/kg (phenylbutyrate and metabolites); clinical meaning: primarily distributes in extracellular fluid
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Oral: ~100% (prodrug is completely hydrolyzed to phenylbutyrate); intraperitoneal: not used clinically
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
GFR 30-59 m L/min: reduce dose by 50%; GFR 15-29 m L/min: reduce dose by 75%; GFR <15 m L/min: contraindicated.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
450-600 mg/m2/day orally in three divided doses; for children <20 kg, use 450 mg/m2/day; maximum 20 g/day.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Start at low end of dosing range (450 mg/m2/day) and titrate based on renal function and tolerability; monitor for fluid overload.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
None.
None
Monitor plasma ammonia levels, neurotoxicity (somnolence, lethargy, confusion) due to elevated phenylacetate; caution in hepatic or renal impairment; contains phenylalanine; avoid use with valproic acid; may cause hyperammonemia if dosing is incorrect; fluid and electrolyte imbalance; growth retardation in pediatric patients; pancreatic enzyme replacement may be needed.
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Known hypersensitivity to glycerol phenylbutyrate or any component; patients with arginase deficiency; patients requiring therapy for hyperammonemia who are unable to swallow capsules or have gastrointestinal obstruction.
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
Avoid high-protein meals without concurrent nitrogen-scavenging therapy; maintain a protein-restricted diet as prescribed. Do not mix the medication with acidic foods or drinks (e.g., orange juice, tomato juice) as it can cause precipitation.
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
Glycerol phenylbutyrate is Pregnancy Category C. No adequate studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2 times human exposure; however, fetal toxicity (reduced fetal weight, skeletal variations) occurred at maternally toxic doses. First trimester risk unknown; second and third trimesters: theoretical risk of maternal ammonia control affecting fetal development.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
No data on excretion in human milk; M/P ratio unknown. Due to potential for adverse effects in nursing infants (ammonia elevation if mother has poor control), caution advised. Consider risk-benefit.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
No specific dose adjustment recommendations. Pharmacokinetics may be altered due to increased plasma volume and renal clearance; dose titration based on ammonia levels is essential. Monitor ammonia weekly initially, then as needed.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
Monitor ammonia levels; glycerol phenylbutyrate is a prodrug that provides phenylbutyrate, which conjugates with glutamine to form phenylacetylglutamine, a nitrogen-scavenging agent excreted in urine. Dosing is weight-based (typically 5-12 m L/m²/day in divided doses) and must be adjusted with hepatic or renal impairment. Avoid use with probenecid as it reduces renal excretion of phenylacetylglutamine. Watch for hypernatremia and metabolic acidosis due to sodium content.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
Take with food or formula to reduce gastrointestinal side effects.,Measure dose using the provided oral syringe for accuracy.,Do not mix with acidic beverages (e.g., fruit juice) as it may precipitate.,Contact physician immediately if vomiting occurs within 20 minutes of dosing.,Maintain adequate hydration to ensure urinary excretion of waste nitrogen.,Store at room temperature, do not freeze.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
"Rimexolone, a corticosteroid with anti-inflammatory activity, may induce the metabolism of glycerol phenylbutyrate via hepatic enzyme induction, particularly CYP3A4. This reduces the conversion of glycerol phenylbutyrate to phenylacetate, decreasing therapeutic efficacy for hyperammonemia management. Clinically, patients may experience elevated ammonia levels, increasing the risk of neurotoxicity and hepatic encephalopathy."
"Concomitant administration of loteprednol, a corticosteroid, with glycerol phenylbutyrate, a nitrogen-binding agent used for urea cycle disorders, may reduce the therapeutic efficacy of glycerol phenylbutyrate. Corticosteroids are known to induce hepatic enzymes involved in drug metabolism, potentially accelerating the clearance of glycerol phenylbutyrate. This interaction could lead to increased ammonia levels and loss of disease control in patients with urea cycle disorders."
"Fluorometholone is a corticosteroid that can induce hepatic enzymes, particularly CYP3A4, potentially accelerating the metabolism of glycerol phenylbutyrate, a prodrug that relies on CYP3A4 for conversion to its active metabolite, phenylacetic acid. This reduction in systemic exposure to phenylacetic acid may decrease the therapeutic efficacy of glycerol phenylbutyrate in managing hyperammonemia in urea cycle disorders. Clinically, this could lead to elevated ammonia levels and breakthrough hyperammonemic episodes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GLYCEROL PHENYLBUTYRATE vs ISOLYTE E IN PLASTIC CONTAINER, answered by our medical review team.
GLYCEROL PHENYLBUTYRATE is a Ammonia Detoxicant that works by Glycerol phenylbutyrate is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This compound is excreted by the kidneys, providing an alternative pathway for waste nitrogen excretion in patients with urea cycle disorders.. ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GLYCEROL PHENYLBUTYRATE and ISOLYTE E IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GLYCEROL PHENYLBUTYRATE is: 450-600 mg/m2/day orally in three divided doses, rounded to the nearest 100 mg; maximum 20 g/day.. The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GLYCEROL PHENYLBUTYRATE and ISOLYTE E IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GLYCEROL PHENYLBUTYRATE is classified as Category C. Glycerol phenylbutyrate is Pregnancy Category C. No adequate studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2 times human exposure; however, fe. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.